Please assess the completion status of the following clinical trial:

Trial Title: Hemostatic Effects of Ulinastatin and Tranexamic Acid in Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Atrial or ventricular septum defect patients requiring cardiac surgery with CPB~* Rheumatic or recessive valvular patients requiring valvular repair or replacement with CPB~* Coronary artery disease patients requiring coronary revascularization surgery with CPB~Exclusion Criteria:~* Non-primary cardiac surgery~* Definite liver or renal dysfunction~* Disorder in coagulation function~* Allergy~* Pregnancy or lactation~* Disabled in spirit or law~* Fatal conditions such as tumour

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Ulinastatin (Type: EXPERIMENTAL): 1,000,000 units of ulinastatin in 50ml solution before skin incision; 50ml saline solution after neutralization
- Tranexamic Acid (Type: EXPERIMENTAL): 15mg/kg tranexamic acid in 50ml solution before skin incision; 15mg/kg tranexamic acid in 50ml solution after neutralization
- Placebo (Type: PLACEBO_COMPARATOR): 50ml saline solution before skin incision; 50ml saline solution after neutralization

Based on this trial design, predict the completion outcome and termination type (if applicable).